Incyte Corp
Change company Symbol lookup
Select an option...
INCY Incyte Corp
TLIS Talis Biomedical Corp
DVN Devon Energy Corp
BCX BlackRock Resources & Commodities Strategy Trust
BRKS Brooks Automation Inc
OPEN Opendoor Technologies Inc
ADI Analog Devices Inc
HD Home Depot Inc
SIEN Sientra Inc
APPF Appfolio Inc
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib). JAKAFI (ruxolitinib) is indicated for the treatment of patients with intermediate or high risk myelofibrosis (MF) and for the treatment of patients with polycythemia vera (PV) having had an inadequate response to or are intolerant of hydroxyurea. As of December 31, 2016, the Food and Drug Administration had granted JAKAFI orphan drug status for MF, PV and essential thrombocythemia. The primary target for ICLUSIG is B Cell Receptor-ABL, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. The Company also has a portfolio of selective janus associated kinases 1 (JAK1) inhibitors.

Price
Delayed
$81.05
Day's Change
-0.34 (-0.42%)
Bid
--
Ask
--
B/A Size
--
Day's High
81.50
Day's Low
79.42
Volume
(Heavy Day)

Today's volume of 2,098,501 shares is on pace to be much greater than INCY's 10-day average volume of 1,270,356 shares.

2,098,501
  • Prev Close
    81.39
  • Today's Open
    80.32
  • Day's Range
    79.42-81.50
  • Avg Vol (10-day)
    1.3M
  • Last (time)
    2:31p ET 05/11/21
  • Last (size)
    100
  • 52-Wk Range
    75.52 - 110.37
    LowHigh
  • (07/07/20 - 03/04/21)
    7.32%
  • 36.9%
  • Market Cap
    17.9B
  • Shares Outstanding
    219.9M
  • 2.17
  • 38.09x
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.8
  • 93.94
  • (% of float 04/15/21)
    2.28

Latest News

May 10, 2021
8:00 pm ET
Globe Newswire
May 04, 2021
7:00 am ET
BusinessWire
6:15 am ET
Accesswire
May 03, 2021
8:00 am ET
BusinessWire
April 27, 2021
8:00 am ET
BusinessWire
April 23, 2021
11:33 am ET
PR Newswire
10:00 am ET
BusinessWire
10:00 am ET
BusinessWire
April 20, 2021
8:00 am ET
BusinessWire
6:45 am ET
PR Newswire
April 19, 2021
4:16 pm ET
Accesswire
4:01 pm ET
BusinessWire
April 13, 2021
8:00 am ET
BusinessWire
April 08, 2021
2:15 pm ET
MarketWatch
11:17 am ET
MarketWatch
7:01 am ET
MarketWatch
6:48 am ET
MarketWatch
6:48 am ET
MarketWatch
6:45 am ET
PR Newswire
April 06, 2021
4:30 pm ET
PR Newswire
March 29, 2021
12:04 pm ET
BusinessWire
March 23, 2021
5:13 am ET
BusinessWire
March 19, 2021
9:40 am ET
MarketWatch
March 18, 2021
4:30 pm ET
BusinessWire
March 11, 2021
8:00 am ET
BusinessWire
March 03, 2021
6:45 am ET
PR Newswire
March 01, 2021
6:00 pm ET
Globe Newswire
February 26, 2021
3:00 am ET
BusinessWire
February 22, 2021
8:00 am ET
BusinessWire
February 19, 2021
8:00 am ET
BusinessWire
February 11, 2021
8:00 am ET
BusinessWire
January 07, 2021
11:09 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.